We further analyzed PTPRT mutation in another combined pan-cancer cohort conducted by ICGC/TCGA and MSK (validation cohort, n = 3418) with similar observations that PTPRT-altered groups tend to have poor progression-free survival and overall survival (log-rank test, P = 0.1 and P = 0.016, respectively, Figures 5(c) and 5(d)). The gene discussed is PTPRT; the disease is cancer.